<DOC>
	<DOCNO>NCT00082667</DOCNO>
	<brief_summary>RATIONALE : Gefitinib may stop growth tumor cell block enzymes necessary growth . It yet know whether surgery effective without gefitinib treat ductal carcinoma situ . PURPOSE : This randomized phase II trial study well gefitinib together surgery work compare surgery alone treatment woman ductal carcinoma situ breast .</brief_summary>
	<brief_title>Gefitinib Followed By Surgery Treating Women With Ductal Carcinoma In Situ Breast</brief_title>
	<detailed_description>OBJECTIVES : Primary - Compare epidermal growth factor receptor ( EGFR ) pathway biomarker modulation tissue sample woman ductal carcinoma situ ( DCIS ) breast treat gefitinib v placebo follow local surgery . - Compare effect regimens cell turnover vivo EGFR-positive vs EGFR-negative patient . Secondary - Compare efficacy regimens estrogen-receptor ( ER ) -positive vs ER-negative HER2-positive v HER2-negative patient DCIS . - Correlate level HER2 extracellular domain biomarker modulation patient treat regimen . OUTLINE : This randomize , pilot study . Patients randomize 1 2 treatment arm . - Arm I : Patients receive oral gefitinib daily 7-14 day day local surgery . Patients undergo lumpectomy mastectomy . - Arm II : Patients receive oral placebo daily 7-14 day day local surgery . Patients undergo local surgery arm I . PROJECTED ACCRUAL : A total 78 patient ( 39 per treatment arm ) accrue study within 1.5 year .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma Situ</mesh_term>
	<mesh_term>Carcinoma , Ductal</mesh_term>
	<mesh_term>Carcinoma , Intraductal , Noninfiltrating</mesh_term>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm ductal carcinoma situ ( DCIS ) breast OR mammogram highly suspicious DCIS No invasive disease Not completely excise Epidermal growth factor receptor ( EGFR ) positive ( &gt; 10 % cell stain ) Planned lumpectomy mastectomy within next 24 week Hormone receptor status : Estrogen receptor status know PATIENT CHARACTERISTICS : Age 35 Sex Female Menopausal status Not specify Performance status ECOG 01 Life expectancy Not specify Hematopoietic Granulocyte count &gt; 1,500/mm^3 Platelet count &gt; 100,000/mm^3 Hepatic Bilirubin &lt; 1.5 mg/dL SGOT ≤ 2 time upper limit normal ( ULN ) SGPT &lt; 1.5 time ULN PT PTT ≤ 1.5 time ULN INR ≤ 1.5 time ULN Renal Creatinine &lt; 1.5 mg/dL Cardiovascular No New York Heart Association class IIV heart disease Pulmonary No acute asthma Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception Random blood sugar &lt; 2.5 time ULN No known hypersensitivity study drug excipients No nonhealing wound fracture No active infection No malignancy within past 5 year except basal cell carcinoma , breast carcinoma , carcinoma situ cervix No psychosis severe depression No concurrent uncontrolled illness PRIOR CONCURRENT THERAPY : Biologic therapy No prior trastuzumab ( Herceptin® ) Chemotherapy At least 1 year since prior chemotherapy No concurrent chemotherapy Endocrine therapy At least 1 year since prior aromatase inhibitor At least 1 year since prior antiestrogens luteinizing hormonereleasing hormone agonist antagonists No concurrent glucocorticoid Concurrent oral contraceptive allow Concurrent hormone replacement therapy allow Radiotherapy At least 1 year since prior radiotherapy No concurrent radiotherapy Surgery See Disease Characteristics Recovered prior oncologic major surgery No prior organ allograft Other Recovered prior therapy ( except alopecia ) More 30 day since prior nonapproved investigational drug No prior definitive local therapy No prior immunosuppressive therapy No prior gefitinib No prior EGFR inhibitor No concurrent cytotoxic drug No concurrent warfarin anticoagulation No concurrent CYP3A4 inducer , include follow : Phenytoin Carbamazepine Barbiturates Rifampin Phenobarbital Hypericum perforatum ( St. John 's wort ) Ethosuximide Griseofulvin Nafcillin Nelfinavir Nevirapine Oxcarbazepine Phenylbutazone Primidone Rifabutin Rofecoxib Sulfamethazine Sulfinpyrazone Troglitazone No concurrent antiretroviral treatment HIVpositive patient</criteria>
	<gender>Female</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>breast cancer situ</keyword>
	<keyword>ductal breast carcinoma situ</keyword>
</DOC>